# Phenyl piperazine derivatives having antiagressive activity.

## Abstract
It has been found that the group of new phenyl piperazine derivatives of formula 3 of the formula sheet and the salts thereof have a strong and selective antiagressive activity. The compounds can be prepared in a manner known for analogous compounds and be processed to the usual compositions.

## Claims
CLAIMS 1. Compounds of formula 3 of the formula sheet and salts thereof with pharmaceutically acceptable acids, in which formula R1 is hydrogen, methyl or a optionally substi tuted phenyl group, R2 is hydrogen or a methyl group or R1 and R2 together with the carbon atom to which they are bound are a cyclic alkyl group having 3 7 C atoms, R3 is a hydrogen atom, a methyl group or an ethyl group, R4 is a trifluoromethyl group, A is a straight or a branched alkyl group having 1 4 C atoms, and Z is an alkyl group having 5 7 C atoms, a phenyl group or a phenyl group substituted by 1, 2 or 3 substituents selected from the group consisting of alkyl, alkoxy, halogen and CF3, a furanyl group, a pyridyl group or a pyrimidyl group, an optionally substituted benzyl, aryl oxy, arylthio, arylsulfonyl, arylsulfinyl or heteroaryloxy group. 2. N 2 4 3 trifluoromethylphenyl 1 pipera ztnyl3ethyl phenoxy acetamide. 3. Pharmaceutical compositions, characterized in that as an active substance they comprise at least one compound of formula 3 of the formula sheet, in which R1 R4, A and Z have the meanings given in Claim 1, or a pharmaceutically acceptable acid addition salt thereof. 4. A method of preparing pharmaceutically active phenyl piperazine derivatives, characterized in that antiagressive active compounds of formula 3 of the formula sheet, in which H R1 R4, H4 A and Z have the meanings mentioned in Claim 1, and salts thereof with pharmaceutically acceptable acids are prepared in a manner known for the synthesis of analogous compounds. 5. A method as claimed in claim 4, characterized in that a compound of formula 4 of the formula sheet is converted with a an ester of a compound of formula 5, or b with an acid halide of formula 6, a mixed anhydride of formula 7 or an ester of formula 8. 6. A method as claimed in claim 4, characterized in that a compound of formula 9 is converted with a compound of formula 10, in which R1 R4, A and Z have the meanings given in Claim 1 and X is a leaving group, such as chlorine, bromine or tosylate. 7. A method as claimed in Claim 4, characterized in that a compound of formula 3 in which R3 is an alkyl group, is prepared by converting a compound of formula 3 not substituted at the nitrogen atom, with a compound R3Y, in which R3 has the above mentioned meaning and Y is halogen or the group S04 g 8. A method as olaimed in Clam 4, characterized in that a compound of formula 11 is converted with a compound of formula 12, in which H 1 H4, A and Z have the meanings given in Claim and X has the meaning given in Claim 6. 9. A method as claimed in Claim 4, characterized in that a compound of formula 13 in which Hal is a halogen atom and R4 is trifluoromethyl is converted with a compound of formula 14 in which R1 R3, A and Z have the meanings given in Claim 1. 10. A method as claimed in Claim 4, characterized in that a compound of formula 15 in which R1 R4, A and Z have the meanings given in Claim 1 is converted with 1,2dibromoethane. 11. A method as claimed in Claim 4, characterized in that a compound of formula 16 is converted with a compound of formula 17, in which R1 R4, A and Z have the meanings given in Claim 1. 12. A method as claimed in Claim 4, characterized in that a compound of formula 18 is converted with a compound of formula 19, in which R1 R4 and Z have the meanings given in Claim 1 and A is the group CH2 CH2 . 13. A method as claimed in Claim 4, characterized in that a compound of formula 9 is converted with a compound of formula 20, in which R1 R4, A and Z have the meanings given in Claim 1. 14. A method as claimed in Claim 4, characterized in that a compound of formula 9 is converted with a compound of formula 12 in the presence of formaldehyde, in which formulae A is the methylene group and R1 R4 and Z have the meanings given in Claim 1. 15. A method of controlling intrapunitive and extrapunitive behaviour and overt agressive behaviour in man and animal, characterized in that an active quantity of a compound of formula 3, in which R1 R4, A and Z have the meanings mentioned in Claim 1, or a salt thereof with a pharmaceutically acceptable acid, is administered. 16. A method of preparing pharmaceutical compositions, characterized in that a compound of Claim 1 is brought into a form suitable for administration. CLAIMS FOR AUSTRIA 1. A method of preparing pharmaceutically active phenyl piperazine derivatives, characterized in that antiagressively active compounds of formula 3 of the formula sheet, in which R1 is sheet, in which R1 is hydrogen, methyl or a optionally substi tuted phenyl group, 2 is hydrogen or a methyl gorup or R1 and R2 together with the carbon atom to which they are bound are a cyclic alkyl group having 3 7 C atoms, 3 is a hydrogen atom, a methyl group or an ethyl group, R4 is a trifluoromethyl group, A is a straight or a branched alkyl group having 1 4 C atoms, and Z is an alkyl group having 5 7 C atoms, a phenyl group or a phenyl group substituted by 1, 2 or 3 substituents selected from the group consisting of alkyl, alkoxy, halo gen and CF3, a furanyl group, a pyridyl group or a pyrimidyl group, an optionally substituted benzyl, aryloxy, arylthio, arylsul fonyl, arylsulfinyl or heteroaryloxy group, and salts thereof with pharmaceutically acceptable acids are prepared in a manner known for the synthesis of analogous compounds. 2. A method as claimed in Claim 1, characterized in that a compound of formula 4 of the formula sheet is converted with a an ester of a compound of formula 5, or b with an acid halide of formula 6, a mixed anhydride of formula 7 or an ester of formula 8. 3. A method as claimed in claim 1, characterized in that a compound of formula 9 is converted with a compound of formula 10, in which R1 R4, A and Z have the meanings given in Claim 1 and X is a leaving group, such as chlorine, bromine or tosylate. 4. A method as claimed in claim 1, characterized in that a compound of formula 3 in which R3 is an alkyl group, is prepared by converting a compound of formula 3 not substituted at the nitrogen atom, with a compound R3Y, in which R3 has he above rentioned meaning and Y is halogen or the group O4 U. 5. A rt ethoc as claimed in Claim 1, characterized in that a compound of formula 11 is converted with a compound of formula 12, in which R1 R4, A and Z have the meanings give n Clai 1 and X has the meaning given inClaim 3. 6. P method as claimed in Claim 1, characterized in that a compound of formula 13 in which Ha is a halogen atom and P.4 is trifluoromethyl is converted with a compound of formula 14 in which R1 R3, A and Z have the meanings giver n C1ain 1. 7. A method as claimed in Claim 1, characterized in that a compound of formula 15 in which R R4, A and Z have the meanings liven in Claim 1 is converted with 1,2 dibromoethane. 8. A rethoc as claimed in Claim 1, characterized in that a ccmound of formula 16 is converted with a compound of forula 17, in which R1 R4, A and Z have the meanings giver in Claim. 9. k method as claimed in Claim 1, characterized in that a compound of formula 18 is converted with a compound of formula 19, in which R1 R4 and Z have the meanings given in Claim 1 and A is the group CH2 CH2 . 10. A method as claimed in Claim 1, characterized in that a compound of formula 9 is converted with a compound of formula 20, in which R1 R4, A and Z have the meanings given in Claim 1. 11. A method as claimed in.Claim 1, characterized in that a compound of formula 9 is converted with a compound of formula 12 in the presence of formaldehyde, in which formulae A is the methylene group and R1 H4 and Z have the meanings given in Claim 1.

## Description
Phenyl piperazine derivatives having antiagressive activity The invention relates to new phenyl piperazine derivatives, to the preparation of these compounds, and to compositions comprising at least one of these compounds as an active substance. Various phenyl piperazine derivatives having a variety of pharmacological properties are known. United States Patent Specification 2,722,529, for example, relates to compounds of formula 1 of the formula sheet, in which B is a straight or branched alkyl group having 2 6 carbon atoms and 0 is an acyl group, sulphonyl group or carbamoyl groups These compounds are said to have a strong sympatholytic activity and sometimes a hypotensive activity. From United States Patent Specification 2,833, 770 is furthermore known a group of compounds of the general formula 2 of the formula sheet, in which formula R is a chlorine atom or a bromine atom, R is hydrogen or a methyl group and m is an integer number from 2 5. Of these compounds a sympatholytic activity is also known. It has been found that phenyl piperazine derivatives of formula 3 of the formula sheet, in which R1 is a hydrogen atom, a methyl group or a substituted or non substituted phenyl group, R2 is a hydrogen atom or a methyl group, or R1 and R2 together with the carbon atom to which they are bound are a cyclic alkyl group having 3 7 C atoms,R3 is a hydrogen atom or an alkyl group having 1 or 2 carbon atoms, R4 is a trifluoromethyl group, A is a straight or branched alkyl group having 1 4 C atoms, and Z is a cycloalkyl group having 5 7 C atoms, a phenyl group or a phenyl group substituted by 1, 2 or 3 substituents selected from the group consisting of alkyl, alkoxy, halogen and CF3, a furanyl group, a pyridyl group or a pyrimidyl group, an optionally substituted benzyl, aryloxy, arylthio, arylsulfonyl, arylsulfinyl or heteroaryloxy group and the salts thereof have a strong antiagressive activity. Some of the compounds belonging to this group moreover have some analgetic activity. Surprisingly, this antiagressive activity of the compounds according to the invention proved not to be associated with the sympatholytic properties described for the above mentioned known and structurally closely related compounds, which properties are undesired for antiagressive agents. Other undesired side effects, such as dopaminolytic, muscle relaxing and sedative properties which are undesired for use as antiagressive agents are also absent in the dosages in which the antiagressive activity occurs It is extremely surprising that the compounds according to the invention show a strong and particularly selective antiagressive activity, since structurally very closely related known compounds have a quite different pharmacological activity pattern. The activity of the compounds ED50 value was determined in a test on antiagressive activity in isolated mice Advances in Pharmacol. 5, 1967 , 79 . In this test, male albino mice were kept isolated for a period of 4 weeks and then selected for the test on the basis of fighting behaviour present The selection criterion is the occurrence of 3 or more fighting periods within 3 minutes after a mouse not kept isolated was placed in the cage of the mouse which had been kept isolated. The compounds to be examined were administered orally to the selected mice. Per dose 5 mice were used. Sixty minutes after administration of the compounds to be tested, the animals were again evaluated for fighting behaviour. The compound to be examined is inactive in the dose administered when this time also 3 or more fighting periods were observed within 3 minutes after a mouse not kept isolated was placed in the case of the mouse which had been kept isolated. From the results obtained the ED50 value in mg of active substance per kg of body weight was calculated. The ED50 values of the 50 compounds according to the invention is smaller than 10 mg kg and in most of the cases is between 1 and 5 mg kg. Since in the compounds according to the invention the sympatholytic activity and also other undesired side effects mentioned of the known compounds were in addition not found, the new compounds are excellently suitable, due to their surprising selective antiagressive activity pattern, for being used in the treatment of intrapunitive and extrapunitive behaviour and overt agressive behaviour in man and animal. For medical use in men is to be considered first of all the control of agressive symptoms in psychiatric illnesses and serious forms of psychopathological agression. As an application possibility in the veterinary field are to be considered in particular those forms of agression which occur in transporting agricultural domestic animals and the mixing of groups of these animals. The quantity, frequency and way of administration may differ for each individual case also dependent on the nature and the severity of the disturbances. In general a dose of 5 500 mg and preferably 25 150 mg per day will be suitable for humane application. For veterinary purposes the dose is preferably 0.1 10 mg kg of body weight. The active compounds according to the invention and their salts can be processed to compositions such as pills, tablets, coated tablets, capsules, powders, injection liquids and the like according to known standard techniques, while using the conventional auxiliary substances such as solid and liquid carrier materials. As examples of pharmaceutically acceptable acids with which the compounds according to the invention can form salts may be mentioned hydrzhloric acid, sulphuric acid, nitric acid, citric acid, fumaric acid, maleic acid, tartaric acid, methanesulfonic acid, benzoic acid and the like. The compounds of formula 3 and their salts can be prepared according to methods suitable for the synthesis of analogous compounds. The invention therefore also relates to the preparation of the new compounds and the salts thereof. Dependent on the symbols of R1 R4, A and Z, the compounds of the general formula 3 can be obtained accor ding to at least one of the methods below a Reaction of a compound of formula 4, in which R3, R4 and A have the above mentioned meanings, with an ester prefer ably the methyl ester of ethyl ester of a compound of formula 5, in which R1, R2 and Z have the above mentioned meanings. The reaction is preferably carried out with an excess of the ester, in a suitable solvent, at a temperature between room temperature and the boiling point of the solvent used see J. Pharm. Soc. Japan, 62 1942 , 531 .b Reaction of a compound of formula 4 with an acid halide of formula 6 or the mixed anhydride of formula 7, or with the ester of formula 8 so called Mukayama ester see Chem. Letters, 1163 , 1975 . This reaction is carried out in an organic solvent, for example, toluene, dioxan, ether, methylene chloride or tetrahydrofuran, at temperatures between room temperature and the boiling point of the solvent used. The compounds according to the invention can also be obtained by reaction of a compound of formula 9 with a compound of formula 10. In these formulae, R1 R4, A and Z have the above mentioned meanings and X is a so called leaving group, preferably chlorine, bromine or tosylate. The reaction may be carried out both with and without an inert organic solvent. Suitable solvents are, for example, methyl ethyl ketone, dimethyl formamide, tetrahydrofuran, petroleum ether, alcohol and acetonitrile. As an acid binder is preferably used NaHC03 or potassium carbonate. The reaction temperature is. usually between room temperature and the reflux temperature of the solvent used, and the reaction duration varies from a few hours to approximately 20 hours. Compounds according to the invention of formula 3, in which R3 is an alkyl group and R1, R2, Rq, A and Z have the above mentioned meanings, may also be prepared by reaction of a compound of formula 3 not substituted at the nitrogen atom with a compound R3Y, in which R3 is alkyl andY is halogen preferably iodine or S04 i. This reaction is usually carried out in a solvent , for example, benzene, DMSO or dimethyl formamide in the presence of a strong base such as, for example, KOH orNaH in anhydrous circumstances at temperatures between room temperature and the reflux temperature of the solvent seeJ. Org. Chem. 14 1949 , 1099 . In similar reaction circumstances, compounds of formula 3 can be prepared by reaction of a compound of formula 11 with a compound of formula 12, in which formulae R1 R4, A, Z and X have the above mentioned meanings. Compounds according to the invention of formula 3, in which R4 is trifluoromethyl, can be obtained by reaction of a compound of formula 13, in which R4 is trifluoromethyl and Hal is halogen, preferably bromine, with a compound of formula 14, in which R1 R3, A and Z have the above mentioned meanings. This reaction is carried out in a solvent, for example, DMSO, in the presence of an acid binder, for example Na2CO3. The reaction mixture is stirred at elevated tempera 0 ture 100 180 C for a few hours see German Offenlegungs schrift 2,024,826 . The compounds of formula 3 can furthermore be prepared by converting a compound of formula 15, in which R1 R4, A and Z have the above mentioned meanings, with 1,2 dibromoethane. The reaction is carried out in an organic solvent such as dioxan or butanol in the presence of an id binder, for example, K2CO3, at a temperature of 20 1200C see Arzneimittel Chemie 27 11 , 1977 , 2077 2086 . The compounds of formula 3 can also be obtained by converting a compound of formula 16 with a compound of for mula 17, in which formulae R1 R44and Z have the above mentioned meanings. This conversion is preferably carried out in a solvent, for example butanol, in the presence of an acid binder, for example K2C03, at temperatures between room temperature and the boiling point of the solvent used see British PatentSpecification 943,739 . Furthermore, the compounds of formula 3 can be prepared in similar reaction circumstances by reaction of a compound of formula 18 with a compound of formula 19, in which formula R1 R4, A and Z have the above mentioned meanings see Coll. Czech. Chem. Comm. 6 1934 , 211 . Compounds of the general formula 3 in which A is the group CEl2 CH2 , can be prepared by converting a compound of formula 9 with a compound of formula 20, in which formula R1 R4 and Z have the above mentioned meanings, The 0 two reaction components are heated at 100 C for 1 6 hours pre ferably without a solvent. However, the starting substances can also be reacted in a solvent such as acetone, methyl ethyl ketone or toluene at temperatures between room temperature and the boiling point of the solvent used. The compounds of the general formula 3, in which R R and Z have the above mentioned meanings and A is the methylene group, can also be obtained by reacting a compound of formula 9 with a compound of formula 12 in the presence of a formaline solution in alcohol, at temperatures between room temperature and the boiling point of the solvent. The invention will now be described in greater detail with reference to the ensuing specific examples. EXAMPLE IN 2 4 3 trifluoromethylphenyl 1 piPerazinyl ethyl 1 phenyl cyclohexane carboxamide.HCl 10 Mmol 2.73 g of Z p4 3 trifluoromethyl phenyl 1 piperazinyl ethylamine were dissolved in 20 ml of methylenechloride. While stirring, a solution of 11 mmol 2.45 g of 1 phenylcyclohexane carbonyl chloride in 10 ml of methylenechloride was added dropwise.After leaving to stand at room temperature for 12 hours, the reaction mixture was evaporated to dryness in vacuo and the residue was recrystallized from methylenechloride ether 1 1 .The material thus obtained was recrystallized once again from ethyl acetate, after which the title compound was obtained having a melting point of 149 150 C. In an analogous manner the following compounds were prepared from the said starting substances 1 N 2 4 3 trifluoromethylphenyl 1 piperazinyl ethyl 1 phenyl cyclopropane carboxamide.HCl, melting point 176.5 178.50C, from 2 4 2 4 3 trifluoromethylphenyl 1 piperazinyl ethylamine and 1 phenyl cyclopropane carbonylchloride. 2 triuorometypeny piperazinyety methyl 1 phenylcyclohexane carboxamide.HCl, melting point 188 190 C from 2 4 3 trifluoromethylphenyl 1 piperazi L C from nyl ethylmethylamine and 1 phenyl cyclohexane carbonyl chloride.3 N 2 4 N 2 4 3 trifl√ºoromethylphenyl 1 piperazinyl ethyl 1 4 chlorophenyl cyclohexane carboxamide.HCl, melting point 134.5 136.50C, from 2 4 3 trifluoromethylpenyl 1 pipe razinylgethylamine and 1 4 chloFphenyl cyclohexane carbo nyl chloride.4 N 2 4 3 trifluoromethylphenyl 1 piperazinyl 1 methyl ethyl2 1 phenyl cyclohexane carboxamide.HCl, melting point 120 1290C, from 1 3 trifluoromethylphenyl l piperazi nyl 2 propylamine and 1 phenyl cyclohexane carbonyl chlo ride.5 N 2 4 , N 2 4 3 trifluoromethylphenyl 1 piperazinyl ethyl diphe nylacetamide.HCl, melting point 103 105 C, from 2 L4 3 trifluoromethylphenyl 1 piperazinyl ethylamine and diphe nylacetyl chloride.6 N N 2 4 3 trifluoromethylphenyl 1 piperazinyldethyl thie nylacetamide.HCl, melting point 143 144.50C from trifluoromethylphenyl 1 piperazinyl3ethylamine and thie nylacetyl chloride.7 N 2 4 trifluoromethylphenyl 1 piperazinyl ethyl 4 chlorophenoxy acetamide.HCl melting point 175.5 177 C, from 2 4 3 trifluoromethylphenyl 1 piperazinyl ethyl amine and 4 chlorophenoxy acetyl chloride. 8 N 2 4 3 trifluoromethylphenyl 1 piperazinyl ethyl thio phenoxy acetamide, melting point 183 1840C, from 2 F4 3 trifluoromethylphenyl 1 piperazinyl ethylamine and thio phenoxy acetic chloride.9 N 2 4 3 trifluEMI7.1 tb oromethylphe tb nyl 1 piperazinyl ethyl phenyl sul fonyl acetamide.HCl, melting point 220 2230C, from trifluoromethylphenyl 1 piperazinyl ethylamine and phenyl sulfonyl acetyl chloride.10 N t2 9 3 trifluoromethylphenyl 1 piperazinypethyl cyclo hexyl acetamine,HCl, melting point 182.5 183.5 C, from 2 4 3 trifluoromethylphenyl 1 piperazinylgethylamine and cyclohexyl acetyl chloride. EXAMPLE IIN 2 4 3 trifluoromethylphenyl 1 Piperazinyle ethyl dimethyl 4 methoxyphenyl acetamide.HCl 25 Mmol 7.7 g of 2 t4 3 trifluoromethylphe nyl 1 piperazinyt ethylamine.HCl were suspended in 10 ml of toluene and 13.2 ml of a 20 Na2C03 solution in water were then added. The mixture was cooled to OOC after which a solution of 25 mmol 5.3 g of dimethyl 4 methoxyphenyl acetyl chloride in 5 ml of toluene was added dropwise while stirring in approximately 20 minutes. The reaction mixture was then stirred at O C for another 45 minutes, after which it was brought at room temperature, at which temperature stirring was continued for another 2 hours. Ether and water were then added. The organic phase was separated and the aqueous layer was extracted twice with ether.The combined organic phase was washed once with 5 NaHC03 solution and then dried on MgS04. After evaporating the solvents the residue was purified chromatographically over silica gel with ethyl acetate as an eluent. The free base thus obtained was taken up in 10 ml of ethanol and 1 equivalent of hydrochloric acid in ethanol was added. The clear solution was then evaporated under reduced pressure and the residue was recrystallized from isopropanol ether. The melting point of the title compound obtained in this manner was 148 149.5 C. The following compounds were obtained in an identical manner 1 N C2 14 3 trifluoromethylphenyl l piperaziny 3ethyl 3 trifluoromethylphenyl acetamide .HCl, melting point 138 141 0C, from 2 4 3 trifluoromethylphenyl 1 piperazinyl ethylamine and 3 trifluoromethylphenyl acetyl chloride. 2 N 2 4 3 trifluoromethylphenyl 1 piperazinyl 2 methyl ethyl 1 phenylcyclohexane carboxamide.maleate, melting point 1660 C, from 2 C43 trifluoromethylphenyl l pipera zinylpropylamine and 1 phenylcyclohexane carbonyl chloride. 3 N 3 4 3 trifluoromethylphenyl 1 piperazinyl propyl 1 phenylcyclohexane carboxamide, melting point 120 129 C from 3 trifluoromethylphenyl 1 piperazinyij propylamine and 1 phenylcyclohexane carbonyl chloride. 4 N 2 4 3 trifluoromethylphenyl 2 piperazinyl ethyl di methyl 4 fluorophenyl acetamide, meltingpoint 89 90 C from 2 t4 3 trifluoromethylphenyl 1 piperazinylgethylamine and dimethyl 4 fluorophenylacetyl chloride. 5 N 2 94 3 trifluoromethylphenyl 1 piperazinyliethyl2 4 methoxyphenyl acetamide, melting point 99 101 C from 2 L4 3 trifluoromethylphenyl 1 piperazinylgethylamine and 4 methoxyphenyl acetyl chloride. 6 N 2 4 3 trifluoromethylphenyl 1 piperazinyl ethyl 4 fluorophenyl acetamide, melting point 950C from 2 L4 3 trifluoromethylphenyl 1 piperazinyl ethylamine and 4 fluoro phenyl acetyl chloride. 7 N 2 4 3 trifluoromethylphenyl 1 piperazinyl ethyl 2,6 dichlorophenyl acetamide, melting point 156 C from 2 t4 3 trifluoromethylphenyl l piperaziny1 ethylamine and 2,6 dichlorophenyl acetyl chloride. 8 N 2 4 3 trifluoromethylphenyl 1 piperazinyldethyl di methyl 3 trifluoromethylphenyl acetamide.maleate, melting point 108 1090C from 1 4 3 trifluoromethylphenyl 1 pipe razinyl ethylamine and dimethyl 3 trifluoromethylphenyl acetyl chloride. 9 N 2 4 trifluoromethylphenyl 1 piperazinyl ethyl 4 trifluoromethylphenyl acetamide, melting point 93 96 0C, from 2 4 3 trifluoromethylphenyl 1 piperazinylethlamine and 4 trifluoromethylphenyl acetyl chloride.10 N L2 94 3 trifluoromethylphenyl 1 piperazinylaethylJdi methyl 4 trifluoromethylphenyl acetamide from 2 4 3 tri fluoromethylphenyl 1 piperazinyl ethylamine and dimethyl 4 trifluoromethylphenyl acetyl chloride.11 N 2 4 3 trifluoromethylphenyl 1 piperazinyl ethyl aphe noxy acetamide.CH3SO3H, melting point 145.5 147.5 C, from 2 L4 3 trifluoromethylphenyl 1 piperazinylgethylamine and phenoxyacetyl chloride. thl 12 N 2 4 3 trifluoromethylphenyl 1 piperazinyl ethyl bis 4 chloro phenoxy acetamide.maleate, melting point 182.5 183.5 C, from 2 4 3 trifluoromethylphenyl 1 piperazinyl ethylamine and bis 4 chlorophenoxy acetyl chloride. EXAMPLE IIIN 2 4 3 trifluoromethylphenyl 1 Piperazinyl ethyl dimethyl phenyl acetamide.HCl 10 Mmol 2.73 g of 2 L4 3 trifluoromethyl phenyl 1 piperazinylethylamine were dissolved in 20 ml of methylenechloride. A solution of 11 mmol 2 g of dimethyl phenyl acetyl chloride in 10 ml of methylene chloride was added dropwise while stirring. After leaving to stand at room temperature for 6 hours, 15 ml of 2 N KOH were added, the organic phase was separated and the aqueous layer was extracted 2 times with methylene chloride. The collected organic phase was washed twice with water and then dried on K2C03. The solution thus obtained was evaporated under reduced pressure and the remaining residue was taken up in 15 ml of ethanol.After adding 1 equivalent hydrochloric acid in alcohol, evaporation was carried out again under reduced pressure, and the salt thus obtained was recrystallized from ethanol ether.The title compound obtained in this manner had a melting point of 134 136.5 C. In the same manner the following compounds were prepared 1 N 2 4 3 trifluoromethylphenyl 1 piperazinyl ethyl 1 4 methylphenyl cyclopentane carbonamide.HCl, melting point 186 1880C, from 2 4 3 trifluoromethylphenyl 1 piperazi nyi ethylamine and 1 4 methylphenyl cyclopentane carbonyl chloride. 2 N L4 g4 3 trifluoromethylphenyl 1 piperazinylqbutyl3 1 phenylcyclohexane carbonamide.oxalate, melting point 81.5 86 0C, from 4 4 3 trifluoromethylphenyl 1 piperazinyl butylamine and 1 phenylcyclohexane carbonyl chloride.3 N 2 N 2 4 3 trifluoromethylphenyl 1 piperazinyl ethyl phenyl acetamide, melting point 85 860C, from 2 L4 3 trifluoro methylphenyl 1 piperazinyl ethylamine and phenyl acetyl chloride.4 N 2 4 3 trifluoromethylphenyl 1 piperazinyl ethyl phe nyl methyl acetamide, melting point 72 730C, from 2 L4 3 trifluoromethylphenyl 1 piperazinylgethylamine and phenyl methyl acetyl chloride. EXAMPLE IVN 2 4 3 trifluoromethylphenyl 1 piperazinyl ethyl cyclo hexyl acetamide 10 Mmol 1.42 g of cyclohexyl acetic acid and 10 mmol 1.4 ml of triethyl amine were dissolved in 25 ml of dry dioxan. A solution of 10 mmol 0.96 ml of chloroformic acid ethyl ester in 5 ml of dry dioxan was then added dropwise at a temperature between 15 and 20 C. After stirring at room temperature for 1 hour a solution 10 mmol 2.73 g of 2 t4 3 trifluoromethylphenyl 1 piperazinylethylamine in 10 ml of dry dioxan was added slowly, the temperature being kept below 30 C. The reaction mixture was stirred for another hour, after which the precipitate formed was sucked off. The filtrate was evaporated under reduced pressure and the residue was recrystallized from cyclohexane. The material thus obtained was recrystallized again from cyclohexane ether, after which the title compound was isolated. It had a melting point of 130 131 0C. The following compounds were obtained in an identical manner 1 N 2 4 3 trifluoromethylphenyl 1 piperazinyl ethyl 2 pyridyl acetamide, melting point 102.5 105.5 C, from 2 t4 3 trifluoromethylphenyl 1 piperazinyl3ethylamine and 2 pyridyl acetic acid. 2 N C2 94 3 triflu EMI11.1 tb methyl SEP tb 2 N 2 4 3trifluorophenyl 1 piperazinyl ethyl 3 pyridyl acetamide.HCl, melting point 153.5 154 C, from 2 L4 3 trifluoromethyphenyl 1 piperazinyl ethylamine and 3 pyridyl acetic acid.